Biogen Says Fourteen Abstracts Highlighting Data From Nephrology Portfolio, Including EMPAVELI And Investigational Felzartamab, Accepted For Presentation At 63rd ERA And 2026 ATC

Loading news article.

Biogen Says Fourteen Abstracts Highlighting Data From Nephrology Portfolio, Including EMPAVELI And Investigational Felzartamab, Accepted For Presentation At 63rd ERA And 2026 ATC | WAPE

Biogen Says Fourteen Abstracts Highlighting Data From Nephrology Portfolio, Including EMPAVELI And Investigational Felzartamab, Accepted For Presentation At 63rd ERA And 2026 ATC

Article summary

Related companies

Comments —